Endoluminal interventions versus surgical interventions for stenosis in vein grafts following infrainguinal bypass

Botelho, Francesco Evangelista; Cacione, Daniel G; Leite, Jose O; Baptista-Silva, Jose CC

doi:10.1002/14651858.cd013702.pub2

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other strategies to improve stent hemocompatibility and reduce restenosis are based on the implementation of nanotechnology ( Zhao et al, 2016 ; Botelho et al, 2021 ; Georgakarakos et al, 2021 ). The use of nanoparticles (NPs) to inhibit restenosis has been reviewed ( Karimi et al, 2016 ).…”

Section: Coronary Angioplasty and Stent Implantationmentioning

confidence: 99%

“…Nevertheless, bypass grafting involving autologous vessels may not be suitable in many cases due to a range of circumstances (i.e., inappropriate graft size, previous diseases, unfavourable operation history or the multiple nature of the vascular occlusion) ( Cai et al, 2021 ; Georgakarakos et al, 2021 ). Additionally, other inconveniences should be highlighted, such as the vein graft failure due to stenosis ( Botelho et al, 2021 ). In a particular example, the internal mammary artery is commonly used for bypassing the left anterior descending artery in patients with CAD.…”

Section: Tissue-engineered Vascular Graftsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases

Barungi

Hernández-Camarero²,

Moreno-Terribas³

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) are the leading causes of death and disability in the world. Among all CVD, the most common is coronary artery disease (CAD). CAD results from the complications promoted by atherosclerosis, which is characterized by the accumulation of atherosclerotic plaques that limit and block the blood flow of the arteries involved in heart oxygenation. Atherosclerotic disease is usually treated by stents implantation and angioplasty, but these surgical interventions also favour thrombosis and restenosis which often lead to device failure. Hence, efficient and long-lasting therapeutic options that are easily accessible to patients are in high demand. Advanced technologies including nanotechnology or vascular tissue engineering may provide promising solutions for CVD. Moreover, advances in the understanding of the biological processes underlying atherosclerosis can lead to a significant improvement in the management of CVD and even to the development of novel efficient drugs. To note, over the last years, the observation that inflammation leads to atherosclerosis has gained interest providing a link between atheroma formation and oncogenesis. Here, we have focused on the description of the available therapy for atherosclerosis, including surgical treatment and experimental treatment, the mechanisms of atheroma formation, and possible novel therapeutic candidates such as the use of anti-inflammatory treatments to reduce CVD.

show abstract